Moors & Cabot’s Viking Therapeutics VKTX Stock Holding History

Moors & Cabot’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,750	Closed	-$636K	–	942
2024 Q1	$636K	Buy	+7,750	New	+$345K	0.03%	422

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Moors & Cabot's VKTX Position: Q2 2024 in Review

Moors & Cabot sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 7,750 shares — an estimated $636K sold.

Moors & Cabot first reported a position in VKTX in Q1 2024 and held it in 1 quarter. The position peaked at $636K in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

Moors & Cabot reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
Moors & Cabot sold 7,750 Viking Therapeutics shares in Q2 2024, an estimated $636K.
Moors & Cabot first reported a position in Viking Therapeutics in Q1 2024 and held it in 1 quarter.
Moors & Cabot's Viking Therapeutics position peaked at $636K in Q1 2024.
387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Moors & Cabot's 13F filing for Q2 2024, filed 9 Aug 2024.